GLP1R and chronic kidney disease: In contrast, relevant data for GLP-1 receptor agonists are limited to the recently published FLOW trial, which demonstrated substantial cardiorenal benefits with subcutaneous semaglutide in people with type 2 diabetes and CKD [22].